KR20220158847A - Btla 효능제 항체 및 이의 용도 - Google Patents

Btla 효능제 항체 및 이의 용도 Download PDF

Info

Publication number
KR20220158847A
KR20220158847A KR1020227039792A KR20227039792A KR20220158847A KR 20220158847 A KR20220158847 A KR 20220158847A KR 1020227039792 A KR1020227039792 A KR 1020227039792A KR 20227039792 A KR20227039792 A KR 20227039792A KR 20220158847 A KR20220158847 A KR 20220158847A
Authority
KR
South Korea
Prior art keywords
ser
leu
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227039792A
Other languages
English (en)
Korean (ko)
Inventor
셰인 크루멘 애트웰
빅터 에이치. 오붕구
앤드류 찰스 벤델
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20220158847A publication Critical patent/KR20220158847A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227039792A 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도 Ceased KR20220158847A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
US62/508,510 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof
KR1020217026470A KR20210106033A (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026470A Division KR20210106033A (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20220158847A true KR20220158847A (ko) 2022-12-01

Family

ID=62245543

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227039792A Ceased KR20220158847A (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도
KR1020197033639A Active KR102294051B1 (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도
KR1020217026470A Ceased KR20210106033A (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197033639A Active KR102294051B1 (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도
KR1020217026470A Ceased KR20210106033A (ko) 2017-05-19 2018-05-11 Btla 효능제 항체 및 이의 용도

Country Status (26)

Country Link
US (2) US10604573B2 (enExample)
EP (1) EP3625257A1 (enExample)
JP (2) JP6790304B2 (enExample)
KR (3) KR20220158847A (enExample)
CN (3) CN110621699B (enExample)
AR (1) AR111752A1 (enExample)
AU (2) AU2018269585B2 (enExample)
BR (1) BR112019021547A2 (enExample)
CA (2) CA3064518A1 (enExample)
CL (1) CL2019003215A1 (enExample)
CO (1) CO2019012756A2 (enExample)
CR (1) CR20190521A (enExample)
DO (1) DOP2019000293A (enExample)
EA (1) EA201992460A1 (enExample)
EC (1) ECSP19082184A (enExample)
JO (1) JOP20190261A1 (enExample)
MA (1) MA49133A (enExample)
MX (1) MX381033B (enExample)
MY (2) MY197425A (enExample)
NZ (1) NZ758360A (enExample)
PE (1) PE20191843A1 (enExample)
PH (1) PH12019502575A1 (enExample)
SA (1) SA519410534B1 (enExample)
TW (4) TWI804044B (enExample)
WO (1) WO2018213113A1 (enExample)
ZA (1) ZA201906954B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2022087441A2 (en) * 2020-10-23 2022-04-28 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
AU2023213914A1 (en) * 2022-01-29 2024-08-15 Hifibio, Inc. Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
ES2577532T3 (es) * 2002-10-25 2016-07-15 Genentech, Inc. Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune
CN101578296A (zh) * 2006-11-15 2009-11-11 梅达雷克斯公司 结合btla的人类单克隆抗体及使用方法
US8563694B2 (en) * 2009-07-31 2013-10-22 Medarex, Inc. Fully human antibodies to BTLA
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
JP2018521959A (ja) * 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Btlaアゴニスト抗体を用いた免疫応答のモジュレーション
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)

Also Published As

Publication number Publication date
CN110621699B (zh) 2023-10-31
MX2019013604A (es) 2019-12-18
MX381033B (es) 2025-03-12
KR102294051B1 (ko) 2021-08-27
TW202233681A (zh) 2022-09-01
MY198277A (en) 2023-08-18
PH12019502575A1 (en) 2020-07-13
KR20190140969A (ko) 2019-12-20
EP3625257A1 (en) 2020-03-25
EA201992460A1 (ru) 2020-03-18
TWI677504B (zh) 2019-11-21
CA3064518A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
US20180334502A1 (en) 2018-11-22
AU2021277743A1 (en) 2021-12-23
NZ758360A (en) 2022-10-28
CL2019003215A1 (es) 2020-04-13
TW201904991A (zh) 2019-02-01
JP2020518288A (ja) 2020-06-25
JP7072622B2 (ja) 2022-05-20
DOP2019000293A (es) 2019-12-15
JOP20190261A1 (ar) 2019-11-05
AU2018269585A1 (en) 2019-10-31
JP6790304B2 (ja) 2020-11-25
JP2021019642A (ja) 2021-02-18
CR20190521A (es) 2020-01-06
US11396545B2 (en) 2022-07-26
TWI747043B (zh) 2021-11-21
TW201946932A (zh) 2019-12-16
ZA201906954B (en) 2021-06-30
TWI804044B (zh) 2023-06-01
AU2018269585B2 (en) 2021-09-02
SA519410534B1 (ar) 2023-11-08
US10604573B2 (en) 2020-03-31
CN117402244A (zh) 2024-01-16
CO2019012756A2 (es) 2020-01-17
PE20191843A1 (es) 2019-12-31
MY197425A (en) 2023-06-16
KR20210106033A (ko) 2021-08-27
CA3184628A1 (en) 2018-11-22
CN110621699A (zh) 2019-12-27
ECSP19082184A (es) 2019-11-30
BR112019021547A2 (pt) 2020-05-12
AR111752A1 (es) 2019-08-14
MA49133A (fr) 2020-03-25
CN117402245A (zh) 2024-01-16
US20200239578A1 (en) 2020-07-30
WO2018213113A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
KR102294051B1 (ko) Btla 효능제 항체 및 이의 용도
CN112513091B (zh) 抗il36r抗体
KR102772851B1 (ko) Trem2 항원 결합 단백질 및 이의 용도
KR102025848B1 (ko) 항―ngf 조성물 및 그의 용도
US9708402B2 (en) Anti-BAFF-anti-IL-17 bispecific antibodies
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR20090088950A (ko) 가공된 항-tslp 항체
KR20190005873A (ko) 항-pacap 항체 및 그의 용도
TW201023890A (en) Antagonists of IL-6 to prevent or thrombosis
AU2014226093A1 (en) Anti-TNF-anti-IL-17 bispecific antibodies
KR102424169B1 (ko) Fc 감마 수용체 iib 및 fc 입실론 수용체에 대한 신규 항체
KR20210044262A (ko) Cd200r 효능제 항체 및 그의 용도
KR20160145158A (ko) Ang2 항체
KR20080099231A (ko) 항체 억제 인자 ⅷ에 대해 유도된 세포 독성 항체
HK40016006A (en) Trem2 antigen binding proteins and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221114

Application number text: 1020217026470

Filing date: 20210820

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230630

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231207

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230630

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I